Navigation Links
Gen-Probe Completes Acquisition of Tepnel Life Sciences
Date:4/8/2009

- Transaction Brings Growth Opportunities in Transplant Diagnostics, Genetic Testing and Pharmaceutical Services, Accelerates European Expansion Strategy -

SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Gen-Probe (Nasdaq: GPRO) announced today that the Company has completed its acquisition of Tepnel Life Sciences, plc, a rapidly growing molecular diagnostics and pharmaceutical services company based in the United Kingdom, for 27.1 pence ($0.40)(1) per share, or approximately 92.8 million pounds sterling ($136.4 million) in total.

"We believe this acquisition brings Gen-Probe new growth opportunities in transplant diagnostics, genetic testing and pharmaceutical services, and also accelerates our European expansion strategy," said Carl Hull, Gen-Probe's president and chief operating officer. "We are very pleased to close the transaction and are ready to work with our new employees and customers to enhance their already strong molecular diagnostics and pharmaceutical services businesses."

The transaction, which was structured as a "scheme of arrangement" under English law, was supported by more than 99% of Tepnel shareholders. The scheme became effective today following confirmation by the High Court of Justice in England and Wales and the registration of the Court documents. In addition, Tepnel's listing on the Alternative Investment Market (AIM) operated by the London Stock Exchange was canceled today. Cash consideration will be sent to Tepnel's shareholders within 14 days.

As previously disclosed, Gen-Probe is financing the acquisition via a revolving credit facility that bears interest at a floating rate 0.6 percent above the one-month London Interbank Offered Rate (LIBOR), which was recently 0.5 percent.

On a non-GAAP basis, Gen-Probe anticipates the transaction will be neutra
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
2. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
5. Carl Hull Named President and Chief Operating Officer of Gen-Probe
6. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
7. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
8. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
9. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. Lucy Shapiro, Ph.D., Elected to Gen-Probe Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)... 2015 HIGHLIGHTS:Q2 2015 Results (all ... , Reported sales were $697 million compared to $701 ... organically by 8%, and changes in foreign currency exchange ... by 1%. , By business unit, organic sales ... 11% in SAFC Commercial. , Reported diluted EPS ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... leader, reports results for the second quarter of ... the group,s results and its performance in different ... transcript:  http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire ... - Q2 results - Performance drivers ...
(Date:7/29/2015)... 2015: +14% CER / 20% of sales) led the regional performance in the ... as well as solid contributions from Korea, India and ... Middle East / Africa (Q2 2015: +3% ... Turkey and the United Kingdom . ... U.S. HPV sales, on demand across all customer classes. The top seven emerging ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... CBDM.T®, the market and business intelligence company, the biofuel market is ... market consists of approximately 85% bioethanol and 15% biodiesel. Bioethanol is ... other hand, Europe is the world leader in biodiesel production and ... , ...
... China, Dec. 1 /PRNewswire-Asia/ -- China Medicine ... "the Company"), a leading,developer and distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... the Company was,awarded GSP (Good Supply Practice ...
... Global Marketing of Ciba TINOSAN SDC in Personal Care, Household ... SAN DIEGO and BASEL, Switzerland, Dec. 1 PURE Bioscience ... a new agreement with Ciba (SWX: CIBN) to market and ... biocide in the personal care, household, and industrial markets worldwide. ...
Cached Biology Technology:CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 2CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 3CBDM.T, the Market and Business Intelligence Company Reviews the Biofuel Market 4China Medicine Corporation Awarded GSP Certification 2China Medicine Corporation Awarded GSP Certification 3PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 2PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 3PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial 4
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... available in German . , In chemical ... of basic or fine chemicals, in catalytic converters of exhaust ... of Karlsruhe Institute of Technology (KIT) and Ruhr-Universitt Bochum (RUB) ... study processes at surfaces of oxides used as catalysts. Their ...
... the Bellvitge Biomedical Research Institute (IDIBELL) have shown that ... a higher level of the protein peroxiredoxin 2 (PRDX2). ... of this protein could be a new therapeutic strategy ... advanced in the online edition of the journal ...
... neighborhoods in which children and adolescents live and spend their ... a healthy diet, get enough exercise or become obese, concludes ... the American Journal of Preventive Medicine . ... methods in geographic information systems (GIS)-based research to determine how ...
Cached Biology News:KIT: Processes at the surface of catalysts 2Geographic information systems demonstrate links between health and location 2
...
... of Br-dUTP results in a stronger signal ... fluorescein-labeled anti-BrdU antibody. Propidium iodide/RNase A ... counterstain the total DNA. Features and Benefits: ... detection than found by using biotin- or ...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
... a direct antibiotic-based selection system for recombinant ... survival, eliminating the need for costly color ... close to 100% accuracy in recombinant selection. ... robot colony picking. This cloning kit can ...
Biology Products: